Table 2.

Concordance between PathVysion and other HER2-testing protocols

Comparison with PathVysion	κ coefficient*	Degree of agreement	Agreement (percentage)	Sensitivity (percentage)	Specificity (percentage)
PharmDx	1.000	Excellent	100	100	100
INFORM (at least six signals per nucleus)	0.916 ± 0.058	Excellent	98	100	94
INFORM (at least five signals per nucleus)	0.799 ± 0.085	Good	91	100	88
INFORM (more than four signals per nucleus)	0.532 ± 0.111	Moderate	76	100	57
CISH (at least six signals per nucleus)	0.876 ± 0.070	Excellent	94	100	94
CISH (at least five signals per nucleus)	0.762 ± 0.091	Good	89	100	88
In-house IHC (positive 3+, negative 0, 1+, 2+)	0.792 ± 0.089	Good	91	89	91
In-house IHC (positive 3+, 2+, negative 0, 1+)	0.475 ± 0.111	Moderate	72	100	57
HercepTest (positive 3+, negative 0, 1+, 2+)	0.645 ± 0.104	Good	83	89	80
HercepTest (positive 3+, 2+, negative 0, 1+)	0.350 ± 0.119	Poor	64	94	49

HER2, human epidermal growth factor receptor 2; CISH, chromogenic in situ hybridisation; IHC, immunohistochemistry. (* errors given as ± SD)